
#### Accepted Manuscript

Title: Multidetection of antibiotics in liver tissue by Ultra-High-Pressure-Liquid-Chromatography tandem Mass Spectrometry





 PII:
 S1570-0232(14)00698-9

 DOI:
 http://dx.doi.org/doi:10.1016/j.jchromb.2014.11.008

 Reference:
 CHROMB 19199

 To appear in:
 Journal of Chromatography B

 Received date:
 11-8-2014

 Revised date:
 4-11-2014

 Accepted date:
 11-11-2014

Please cite this article as: A. Freitas, J. Barbosa, F. Ramos, Multidetection of antibiotics in liver tissue by Ultra-High-Pressure-Liquid-Chromatography tandem Mass Spectrometry, *Journal of Chromatography B* (2014), http://dx.doi.org/10.1016/j.jchromb.2014.11.008

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Highlights:					
The proposed method allows to determine 39 antibiotics in liver simultaneously; Validation process shows the good performance of the method;					
The present method is a huge improvement for laboratories involved in food safety control.					

10	Multidetection of antibiotics in liver tissue by Ultra-High-
11	Pressure-Liquid-Chromatography tandem Mass Spectrometry
12 13 14	Andreia Freitas <sup>1,2</sup> , Jorge Barbosa <sup>1,2</sup> , Fernando Ramos* <sup>2,3</sup>
15	<sup>1</sup> INIAV-LNIV, Laboratório Nacional de Investigação Veterinária, Estrada de Benfica,
16	701, 1549-011 Lisboa, Portugal
17	
18	<sup>2</sup> CEF-Center for Pharmaceutical Studies, Health Sciences Campus, Pharmacy Faculty,
19	University of Coimbra, Azinhaga de Santa Comba, 3000-548 Coimbra, Portugal
20	
21	<sup>3</sup> CNC-Centre for Neuroscience and Cell Biology, Health Sciences Campus, Pharmacy
22	Faculty, University of Coimbra, Azinhaga de Santa Comba, 3000-548 Coimbra,
23	Portugal
24	
25	
26	*Corresponding author
27	Phone number: + (351) 239 488492
28	Fax number: + (351) 239 488503
29	Email: <u>fjramos@ci.uc.pt</u>
30	<u>framos@ff.uc.pt</u>
31 32	
33	
34	
35	
36	

36 37	Abstract
38	
39	A multiresidue quantitative screening method covering 39 antibiotics from 7 different
40	families by Ultra-High-Pressure-Liquid-Chromatography tandem Mass Spectrometry
41	(UHPLC-MS/MS) is described. Sulfonamides, trimethoprim, tetracyclines, macrolides,
42	quinolones, penicillins and chloramphenicol are simultaneously detected in liver tissue.
43	A simple sample treatment method consisting of extraction with a mixture of
44	acetonitrile and ethylenediaminetetraacetic acid (EDTA) followed by solid-phase
45	extraction (SPE) with a hydrophilic-lipophilic balanced (HLB) cartridge was developed.
46	The methodology was validated, in accordance with Decision 2002/657/EC, by
47	evaluating the following required parameters: decision limit (CC $\alpha$ ), detection capability
48	(CC $\beta$ ), specificity, repeatability and reproducibility. The precision, in terms of the
49	relative standard deviation, was under 22% for all of the compounds, and the recoveries
50	were between 80% and 110%. The CC $\alpha$ and CC $\beta$ were determined according to the
51	maximum residue limit (MRL) or the minimum required performance limit (MRPL),
52	when established.
53	
54	
55	Keywords: Antibiotics; multiclass; multidetection; UHPLC-MS/MS; liver; validation.
56	
57	
58	

58	

#### 59 **1. Introduction**

61	Antibiotics are widely used for therapeutic and prophylactic purposes in food-producing
62	animals and to promote animal growth [1]. The use of antibiotics as growth promoters is
63	considered fraudulent in Europe because it can lead to residues of these compounds
64	persisting in edible matrices. These antibiotic residues can result in allergic reactions in
65	some hypersensitive individuals and in the appearance of bacterial strains that are
66	resistant to drugs that are used in both veterinary and human medicine [2], which is
67	currently considered a huge worldwide concern.
68	For that reason, the European Community determined the need for the mandatory
69	control of the veterinary drugs in food from animal origin designated for human
70	consumption [3]. For permitted veterinary drugs, the maximum residue limits (MRL) in
71	foodstuff of animal origin were established and are listed in the EU Commission
72	Regulation 37/2010 [4, 5]. Food products containing concentrations of antibiotics
73	exceeding the established MRL are inappropriate for human consumption. In the case of
74	some non-authorized substances, a minimum required performance limit (MRPL) has
75	been set to harmonize the analytical performance of the methods used in different
76	laboratories [6, 7].
77	A wide variety of edible matrices must be monitored for the presence of veterinary
78	residues, including muscle, liver, kidney, fat, milk, eggs, fish and honey. Nevertheless,
79	there are relatively few multidetection and multiclass methods for the determination of
80	antibiotics in liver tissue. There are still very few methods describing approaches for
81	analyzing different classes of compounds, particularly for their determination in liver

- tissue [8, 9]. To our knowledge, the only available method for the determination of an
- 83 extensive number of antibiotics from several classes in such a matrix was published by

84	Kaufmann et al [8], who detected 100 veterinary drugs in muscle, liver and kidney
85	tissues using UPLC-ToF-MS. The main constraint with using ToF-MS methodologies is
86	related to the fact that it is impossible to use them for confirmation purposes because
87	ToF-MS is not yet included in the regulations [6].
88	There are also some methods that group a few families of compounds, such as the one
89	presented by Shao et al. [9], who developed a multiclass confirmatory method for
90	tetracyclines and quinolones in muscle, liver and kidney tissues using UHPLC-MS/MS.
91	However, the common procedures described in the literature for the determination of
92	antibiotics in liver tissue only include groups of related compounds [10-14]
93	When working with liver tissue and developing the sample preparation methodology,
94	one of the principal obstacles is related to the complexity associated with the high
95	protein and fat contents in this matrix, which often interfere in the analytical
96	performance. Additionally, the high enzymatic activity in liver tissue can be responsible
97	for the fast degradation of labile compounds, which leads to significant losses during
98	sample preparation. Another issue to be considered is that the simultaneous
99	determination of antibiotics from different pharmacologic families in complex
100	biological matrices is constrained by differences in the physicochemical properties of
101	the compounds [15, 16], a fact that makes developing the sample extraction method a
102	challenge that can only be overcome by reaching a compromise that better fits the
103	purpose of the multiclass method.
104	The lack of methodologies for screening of antibiotics in liver demanded for new
105	developments in order to fulfill the requirements of the control program and,
106	consequently, improve food safety. Considering all of these aspects and the need for a
107	reliable and efficient method for the determination of antibiotics in liver tissue while
108	improving the time of analysis for several groups of compounds and the cost-

109	effectiveness, the aim of this work was to develop a multiclass and multidetection				
110	method using UHPLC-MS/MS for the detection of antibiotics from seven families				
111	(sulfonamides, trimethoprim, tetracyclines, macrolides, quinolones, penicillins and				
112	chloramphenicol). To use the method in routine analysis and official control, it was				
113	validated according the requirements described in the European Commission Decision				
114	2002/657/EC [6].				
115 116 117	2. Material and Methods				
118	2.1. Reagents, Solvents and Standard Solutions				
119	All of the reagents and solvents used were of analytical grade, with the exception of the				
120	chemicals used for the mobile phase, which were of high-performance liquid				
121	chromatography grade. Methanol, acetonitrile, n-hexane and formic acid were supplied				
122	by Merck (Darmstadt, Germany). Ethylenediaminetetraacetic acid (EDTA) was				
123	purchased from Sigma-Aldrich (Madrid, Spain). All of the standards of the				
124	sulfonamides, tetracyclines, penicillins, macrolides, quinolones, trimethoprim and				
125	chloramphenicol were supplied by Sigma-Aldrich (Madrid, Spain). The individual				
126	standards are listed in Table 1. The following six internal standards were used:				
127	demethyltetracycline for the tetracyclines; penicillin V for the penicillins; lomefloxacin				
128	for the quinolones; roxithromycin for the macrolides; sulfameter for the sulfonamides				
129	and trimethoprim; and chloramphenicol-fifth-deuterated (d5) for chloramphenicol. All				
130	of the internal standards were provided by Sigma-Aldrich. For all of the substances,				
131	stock solutions of 1 mg mL <sup>-1</sup> were prepared by weighing the appropriate amount of				
132	standard, diluting it in methanol, and storing it at -20°C for one year. Suitable dilutions				

- 133 were also prepared to have convenient spiking solutions for both the validation process
- 134 and the routine analyses. Working solutions were stored at -20°C for one month.
- 135

#### 2.2. Instrumentation 136

136	2.2. Instrumentation
137	For the sample preparation, the following equipment was used: Mettler Toledo PC200
138	and AE100 balances (Greifensee, Switzerland), a Heidolph Reax 2 overhead mixer
139	(Schwabach, Germany), a Heraeus Megafuge 1.0 centrifuge (Hanau, Germany), a
140	Turbovap Zymark Evaporator (Hopkinton, MA, USA) and Whatman Mini-Uniprep
141	PVDF 0.45 µm filters (Clifton, NJ, USA). A vacuum manifold was used for the solid
142	phase extraction (SPE) with an Oasis HLB polymeric sorbent cartridge (3 mL, 200 mg)
143	(Waters, Milford, MA, USA). Chromatographic separation and mass spectrometry
144	detection were performed using a Xevo TQ MS-Acquity UPLC system coupled to a
145	triple quadrupole tandem mass spectrometer from Waters (Milford, MA, USA). The
146	electrospray ion source (ESI) was used both in positive and negative modes with data
147	acquisition in the multiple reaction monitoring mode (MRM), and the Masslynx 4.1
148	software (Waters) was used for data processing. The MRM optimized conditions are
149	presented in Table 1. The UHPLC system consisted of a vacuum degasser, an
150	autosampler and a binary pump equipped with an analytical reverse-phase column
151	(Acquity HSS T3 2.1 x 100 mm with 1.8 $\mu$ m particle size, Waters). A flow rate of 0.45
152	mL min <sup>-1</sup> was used with the following mobile phases: [A] formic acid $0.1\%$ (v/v) in
153	water and [B] acetonitrile. The following gradient program was used: 0-5 min from
154	97% to 40% [A]; 5-9 min from 40% to 0% [A]; 9-10 min from 0% back to 97% [A];
155	11-12 min 97% [A]. Column and autosampler were maintained at 40°C and 10°C,
156	respectively. A 20 $\mu$ L aliquot (full loop) was injected onto the analytical column.
157	

#### 158 2.3. Sample preparation

159 Two grams of minced and mixed liver tissue was weighed into a 20 mL glass centrifuge 160 tube. The internal standard solution was added, and the sample was vortexed for 30 s 161 and allowed to stand in the dark for at least 10 min. The sample was extracted by shaking using a Reax shaker for 10 min with 10 mL of acetonitrile and 1 mL of 0.1 M 162 163 EDTA. After that, the sample was left in the ultrasound bath for 20 min. Following 164 centrifugation for 10 min at  $4000 \times g$ , the supernatant was transferred into a new tube and 165 evaporated to near dryness (1 mL). Water (5 mL) was added, and the solution was 166 vortexed for 15 s. The solutions were then submitted to a clean-up step using SPE Oasis 167 HLB cartridges, which were preconditioned with acetonitrile (10 mL) and water (10 168 mL). After passing the aqueous extract through the columns using gravity, the cartridges were washed with water (5 mL) and then dried under reduced pressure for 169 170 approximately 5 min. The elution was performed with acetonitrile (10 mL). The eluate 171 was evaporated to near dryness (0.5 mL) under a gentle stream of nitrogen and 400  $\mu$ L 172 of mobile phase [A] was added. To this extract n-hexane (2 mL) was added and the 173 solution vortexed for 30 s. After centrifugation for 10 min at  $4000 \times g$ , the n-hexane layer was removed. The final extract was filtered through a 0.45  $\mu$ m PVDF Mini-uniprep<sup>1M</sup>, 174 175 transferred to vials and analyzed by UHPLC-MS/MS under the MRM optimized 176 conditions described in Table 1. 177

178 2.4. Validation procedure

179 In-house validation was performed following the method described by the EU

180 Commission Decision 2002/657/EEC [6] that requires the evaluation of the method in

181 terms of the specificity, recovery, repeatability, reproducibility, decision limit ( $CC\alpha$ )

182 and detection capability (CC $\beta$ ).

183	By analyzing 20 blank liver samples from different animal species (bovine, swine,
184	ovine, and poultry) to find possible peaks that could interfere with the detection of the
185	target analytes, the specificity of the method was assessed. Afterwards, the same 20
186	samples were spiked with all of the compounds of interest at the validation level (VL)
187	(Table 2) to prove the identification capability of the method and once again its
188	specificity. Calibration curves using spiked samples were assembled using the following
189	five concentration levels, 0.5xVL, 1.0xVL, 1.5xVL, 2.0xVL and 3.0xVL, and the
190	analyses were carried out on three different days with different operators. Six replicates
191	of the 0.5xVL, 1.0xVL and 1.5xVL concentration levels were performed each day to
192	determine the precision of the method (in terms of the repeatability and reproducibility)
193	and the recovery. The recovery was estimated as a ratio between the obtained
194	concentration and the real concentration.
195	The critical concentrations, CC $\alpha$ and CC $\beta$ , were calculated according to the following
196	equations [6]:
197	$CC_{\alpha} = \mu_N + 2.33 \times \sigma_N$ (Equation 1, for compounds without MRLs)
198	$CC_{\alpha} = MRL + 1.64 \times \sigma_{MRL}$ (Equation 2, for compounds with established MRLs)
199	$CC_{\beta} = CC_{\alpha} + 1.64 \times \sigma_{VL}$ (Equation 3)
200	where $\mu_N$ is the mean of the noise amplitude of twenty blank samples; $\sigma_N$ is the standard
201	deviation of the noise amplitude of twenty blank samples at the retention time of the
202	target analyte; and $\sigma_{MRL}$ or $\sigma_{VL}$ is the standard deviation at the MRL or VL level in the
203	twenty spiked blank samples at that level. For all of the determinations, the peak areas
204	of both the analytes and the corresponding internal standards were measured, and the
205	analyte/internal standard area ratios were determined. Internal standards were chosen
206	for their similar physicochemical behaviors to those of the antibiotics being monitored
207	[17].

208

#### 209 3. Results and discussion

210 The major challenge in the determination of veterinary drugs in biological samples, 211 usually in residual concentrations, lies in sample preparation. Our knowledge and 212 experience from previously developed multiclass methods in milk, fish and bovine 213 muscle [17-19] was the starting point for the present method. In these previously work, 214 the appropriated solvents, for the extraction of the target compound, were already 215 studied and, starting from that knowledge, a new method, to be used in liver, was 216 developed. Thus, the best option for use as the extraction solvent, in terms of the 217 recovery, is an organic extractant, specifically acetonitrile. Aqueous solvents failed to 218 extract the less polar compounds. The same conclusion is expressed in other available 219 publications, though those extractions were performed on different matrices [8, 20], 220 where acetonitrile is preferred over methanol and ethyl acetate, because these last two 221 solvents can be responsible for extracting matrix components that can interfere in the 222 detection. Additionally, it is important to add that acetonitrile, aside from being an 223 efficient extraction solvent, promotes the precipitation of proteins, thereby turning this 224 step into one that is important for obtaining a clean extract. Some of the target 225 antibiotics, such as tetracyclines, quinolones and macrolides, can easily form chelate 226 complexes with bi- and trivalent metal cations present in the sample extraction solution. 227 These can lead to lower recoveries; to prevent their formation, a chelate agent with a 228 similar behavior should be used to control the problem and increase the recoveries. For 229 that reason, EDTA is often used during the liquid extraction, and it has been determined 230 to improve the extraction efficiencies of tetracyclines, quinolones and macrolides. 231 Compared with muscle tissue, liver tissue is a much more complex matrix because of its 232 high protein content, enzymatic activity and fat content. Therefore, to prevent possible

chromatographic interferences and ion suppression or enhancement, further clean-upsteps during the sample preparation were optimized.

235 The use of solid-phase extraction prior to mass spectrometric detection can be a huge 236 advantage to decrease the effects of ion suppression caused by components of liver 237 tissue. To control the possible losses of target antibiotics, the best option is to use a 238 multiclass selectivity cartridge that can fit the diverse physicochemical properties of all 239 of the target antibiotics. The best option, in terms of selectivity, is to use a sorbent 240 composed of a hydrophilic-lipophilic balance modified polymer (OASIS HLB), which 241 is known to have a very broad selectivity for polar compounds [8, 21]. The solid-phase 242 extraction is followed by concentration through evaporation under a gentle stream of 243 nitrogen, without evaporation to total dryness, to avoid a long evaporation process. The instability of antibiotics along with the higher affinity of some polar compounds for 244 245 aqueous phase possibly remaining present in the cartridge and being eluted together 246 with the acetonitrile are the main reasons for this procedure [22]. After reconstitution 247 with the mobile phase, a thin lipidic layer was observed. To remove that layer and 248 prevent such interference in the mass spectrometric detection, a deffating step was 249 performed via the addition of n-hexane. After discarding the n-hexane layer, the final 250 extract was injected and analyzed using UHPLC-MS/MS.

The UHPLC-MS/MS parameters, in terms of chromatography and detection, were previously optimized. The mobile phase, flow rate and gradient steps were selected to achieve the best chromatographic separation and peak shape, along with a short run time. The conditions described above allowed the determination of the 39 compounds in less than 10 min. To fulfill the identification criteria described in Decision 2002/657 [6], two ion transitions must be controlled for each compound. The ideal MRM conditions (Table 1) were achieved through the direct infusion into the detector of each individual

258	standard solution at a concentration of 10 $\mu$ g mL <sup>-1</sup> . For positive ionization, which is the
259	case for all of the compounds except chloramphenicol, the use of formic acid in the
260	mobile phase works as a promoter of positive ionization and consequently improves the
261	detection. In Figure 1, individual MRM chromatograms of one compound per family of
262	monitored antibiotics obtained from a spiked bovine liver sample at the corresponding
263	validation level (VL) are presented.
264	The method was validated in accordance with the European Commission Decision
265	2002/657/EC [6], and the following parameters were evaluated: specificity, recovery,
266	precision (as repeatability and reproducibility) decision limit (CC $\alpha$ ) and detection
267	capability (CCβ).
268	The specificity of the method was assessed by analyzing 20 blank samples of liver
269	tissue of different species (bovine, swine, ovine, and poultry) to verify the absence of
270	interference above a signal-to-noise ratio of 3 at the retention time of the target
271	compounds that could compromise their detection and identification. Additionally, in
272	the spiked blank samples, all of the identification criteria [6] were fulfilled without any
273	false negative results, again proving the specificity of the method for the species
274	analyzed. Considering the proved specificity and that no major differences were found
275	between the 20 blank and spiked samples, only one animal species (bovine) was used
276	for the next validation steps. This choice was based on the fact that bovine liver tissue is
277	a matrix that is very often consumed.
278	The results obtained for the precision (repeatability and reproducibility) as the relative
279	standard deviation (RSD), recovery, CC $\alpha$ and CC $\beta$ are summarized in Table 2. The
280	precision and recovery were calculated at the VL that corresponds to the MRL for those
281	compounds that had it. For repeatability and reproducibility, the highest RSDs of 16%
282	and 24%, respectively, were obtained for sulfisoxazole. All of the other compounds had

283 RSDs under these values. The recovery was calculated as a ratio between the 284 determined concentration in a spiked sample and the real concentration. The range of values obtained were between 81 and 110%, thus falling into the acceptable range [6]. 285 286 Both the precision and recovery are mandatory parameters in validation because they 287 measure the variability during the analytical process and can be used to analyze and 288 prove the robustness of the method. 289 The two critical concentrations,  $CC\alpha$  and  $CC\beta$ , were determined from the calibration 290 curves obtained from the bovine blank liver samples spiked at five concentration levels 291 (0.5, 1, 1.5, 2 and 3xVL) and the application of the equations described above 292 (equations 1, 2 and 3), keeping in mind that not all of the compounds had an established 293 MRL. Antibiotics without a tolerance level (MRL) had lower CCa and CCB values that 294 were closer to the limit of detection of the method, although in the other cases, these 295 concentrations were always above the MRL.

296

297

#### 298 4. Conclusions

299 An analytical method is proposed for the simultaneous determination of 39 antibiotics from 7 different classes in liver tissue. The developed method is able to determine the 300 301 presence of compounds from the sulfonamides, tetracyclines, macrolides, quinolones, 302 chloramphenicol, penicillins and trimethoprim in a single run using UHPLC-MS/MS, 303 providing a possible way to significantly reduce the time required to analyze one 304 sample. The developed method was fully validated and fulfilled all of the criteria 305 specified by the European Union Decision 2002/657/EC [6], proving that it is suitable 306 for routine analysis and quantitative screening purposes for official control, with the 307 possibility of extending the method for antibiotic confirmation. Although the main part

308	of the validation	procedure was	performed o	only for bovine	samples, its	specificity

309 proved that the method can be used for swine, ovine and poultry liver tissue.

- 310 Because there are a limited number of publications reporting methods for the
- 311 simultaneous analysis of antibiotics in liver tissue, the present method is a huge
- improvement for laboratories that are involved in food safety control and have a large
- 313 number of samples and antibiotics to analyze.
- 314

#### 315 5. References

- 316 [1] R. Companyó, M. Granados, M. D. Prat, Antibiotics in food: Legislation and
- 317 validation of analytical methodologies, Anal Bioanal Chem 395 (2009) 877–891.

318

- 319 [2] R. Laxminarayan, A. Duse, C. Wattal, A. K. M. Zaidi, H. F. L. Wertheim, N.
- 320 Sumpradit, E. Vlieghe, G. L. Hara, I. M. Gould, H. Goossens, C. Greko, A. D. So. M.
- 321 Bigdeli, G. Tomson, W. Woodhouse, E. Ombaka, A. Q. Peralta, F. N. Qamar, F. Mir, S.
- 322 Kariuki, Z. A. Bhutta, A. Coates, R. Bergstrom, G. D. Wright, E. D. Brown, O. Cars,
- 323 Antibiotic resistance-the need for global solutions, Lancet Infect Dis 13 (2013) 1057–
- 324 1098.
- 325
- 326 [3] European Commission (1996). Council Directive 96/23/EC of 29 April 1996 on
- 327 measures to monitor certain substances and residues thereof in live animals and animal
- 328 products and repealingDirectives85/358/EEC and 86/469/EEC and Decision
- 329 89/187/EEC and 91/664/EEC. Official Journal of the European Communities, L125, 10-

330 32.

332	[4] - European Commission (2009). Regulation (EC) No. 470/2009 of the European
333	Parliament and of the Council of 6 May 2009: laying down Community procedures for
334	the establishment of residue limits of pharmacologically active substances in foodstuffs
335	of animal origin, repealing Council Regulation (EEC) No. 2377/90 and amending
336	Directive 2001/82/EC of the European Parliament and of the Council and Regulation
337	(EC) No. 726/2004 of the European Parliament and of the Council. Official Journal of
338	the European Union, L152, 11-22.
339	
340	[5] - European Commission (2010). Commission Regulation (EU) No. 37/2010 of 22
341	December 2009: on pharmacologically active substances and their classification
342	regarding maximum residue limits in foodstuffs of animal origin. Official Journal of the
343	European Union, L15, 1-72.
344	
345	[6] - European Commission (2002). Decision (2002/657/EC) of 12 August 2002
346	implementing Council Directive 96/23/EC concerning the performance of analytical
347	methods and interpretation of results. Official Journal of the European Communities,
348	L221, 8-36.
349	
350	[7] - SANCO (2007). CRLs view on state of the art analytical methods for national
351	residue control plans, CRL Guidance Paper (7 December 2007), 1-8.
352	
353	[8] - A. Kaufmann, P. Butcher, K. Maden, M. Widmer, Quantitative multiresidue

- 354 method for about 100 veterinary drugs in different meat matrices by sub 2-μm
- 355 particulate high-performance liquid chromatography coupled to time of flight mass
- 356 spectrometry, J Chromatogr A 1194 (2008) 66–79.

$\gamma$	-	-
- 1	n	1
0	J	

358	[9] - B. Shao, X. Jia, Y. Wu, J. Hu, X. Tu, J. Zhang, Multi-class confirmatory method
359	for analyzing trace levels of tetracyline and quinolone antibiotics in pig tissues by ultra-
360	performance liquid chromatography coupled with tandem mass spectrometry, Rapid
361	Commun Mass Sp 21 (2007) 3487–3496.
362	
363	[10] – H. Berrada, F. Borrull,, G. Font, , J. C. Moltó,, R. M. Marcé, Validation of a
364	confirmatory method for the determination of macrolides in liver and kidney animal
365	tissues in accordance with the European Union regulation 2002/657/EC, J Chromatogr
366	A 1157:1-2 (2007) 281-288.
367	
368	[11] - E. A. Christodoulou, V. F. Samanidou, I. N. Papadoyannis, Development of an
369	HPLC multi-residue method for the determination of ten quinolones in bovine liver
370	and porcine kidney according to the European Union Decision 2002/657/EC, J Sep Sci
371	31:1 (2008) 119–127.
372	
373	[12] - A. R. Shalaby, N. A. Salama, S. H. Abou-Raya, W. H. Emam, F. M. Mehaya,
374	Analytical Methods Validation of HPLC method for determination of tetracycline
375	residues in chicken meat and liver, Food Chem 124 (2011) 1660-1666.
376	
377	[13] – X. Xia, X. Li, S. Ding, J. Shen, Validation of a method for the determination of
378	chloramphenicol in poultry and swine liver by ultra-performance liquid
379	chromatography coupled with tandem mass spectrometry, J AOAC Int. 93:5 (2010)
380	1666-1671.

382	[14] – Y. Zhang, Z	X. Xu, X. Qi, W.	Gao, S. Sun, X. L	i, C. Jiang, A.	Yu, H. Zhang, Y.
-----	--------------------	------------------	-------------------	-----------------	------------------

- 383 Yu, Determination of sulfonamides in livers using matrix solid-phase dispersion
- extraction high-performance liquid chromatography, J Sep Sci 35:1 (2012) 45–52.
- 386 [15] H.F. De Brabander, H. Noppe, K. Verheyden, J. V. Bussche, K. Wille, L.
- 387 Okerman, L. Vanhaecke, W. Reybroeck, S. Ooghe, S. Croubels, Residue analysis:
- Future trends from a historical perspective, J Chromatogr A 1216 (2009) 7964–7976.
- 389
- 390 [16] B. Kinsella, J. O'Mahony, H. Cantwell, A. Furey, M. Danaher, Current trends in
- 391 sample preparation for growth promoter and veterinary drug residue analysis. J
- 392 Chromatogr A 1216 (2009) 7977-8015.
- 393

394 [17] - A. Freitas, J. Barbosa, F. Ramos, Development and validation of a multi-residue

and multiclass ultra-high-pressure liquid chromatography-tandem mass spectrometry

screening of antibiotics in milk, Int Dairy J 33:1 (2013) 38–43.

- 397
- 398 [18] A. Freitas, S. Leston, J. Rosa, M. C. Castilho, J. Barbosa, P. Rema, M. A. Pardal,

399 F. Ramos, Multi-residue and multi-class determination of antibiotics in gilthead sea

- 400 bream (Sparus aurata) by ultra high-performance liquid chromatography-tandem mass
- 401 spectrometry, Food Addit Contam Part A 31:5 (2014) 817–826.
- 402
- 403 [19] A. Freitas, J. Barbosa, F. Ramos, Multi-residue and multi-class method for the
- 404 determination of antibiotics in bovine muscle by ultra-high-performance liquid
- 405 chromatography tandem mass spectrometry, Meat Sci 98 (2014) 58–64.
- 406

407	[20] – S. Bogialli,	A. Di Corcia,	Recent application	ons of liquid	chromatography-mass

- 408 spectrometry to residue analysis of antimicrobials in food of animal origin, Anal
- 409 Bioanal Chem 395 (2009) 947-966.
- 410
- 411 [21] N. Fontanals, R. M. Marcé, F. Borrull, Overview of the novel sorbents available
- 412 in solid-phase extraction to improve the capacity and selectivity of analytical
- 413 determinations, Contrib Sci 6:2 (2010) 199–213.
- 414
- 415 [22] A. Freitas, S. Leston, J. Barbosa, F. Ramos, Liquid-Chromatography: Review on
- the last developments on the detection of antibiotics in food-producing animals. In F.
- 417 Ramos (Ed.), Liquid Chromatography Principles, Technology and applications, Nova
- 418 Science Publishers Inc, New York, 2013, pp. 99-139.

- 419
- 420
- 421

#### USCRIPT ΕD Ŵ Д CCEP Ŀ.

## 421 422 423 $\label{eq:main_stable_loss} \begin{array}{l} Table \ 1 - \mbox{Multiple reaction monitoring (MRM) acquisition conditions for each antibiotic and for the internal standards (IS) used. \end{array}$

		ESI	Precursor ion ( <i>m</i> / <i>z</i> )	Product ions ( <i>m/z</i> )	Cone voltage (V)	Collision energy (eV
	sulfapyridine	+	250.3	156.3/92.3	30	15
	sulfadiazine	+	251.2	156.2/92.2	30	15
	sulfamethoxazole	+	254.4	156.4/92.2	30	20
	sulfathiazole	+	256.4	156.3/92.3	25	15
	sulfisoxazole	+	268.3	156.2/113.2	25	15
	sulfamethiazole	+	271.0	156.2/108.1	25	15
	sulfisomidine	+	279.4	186.3/124.4	30	16
Sulfonamides	-	+				
Sunonannues	sulfamethazine		279.4	156.3/124.5	30	15
	sulfamethoxypyridazine	+	281.2	156.2/92.2	30	15
	sulfachloropyridazine	+	285.3	92.3/156.3	30	28
	sulfadoxine	+	311.4	156.4/92.3	30	18
	sulfadimethoxine	+	311.4	156.4/92.3	30	20
	sulfanilamide	+	173.2	92.1/156.2	30	25
	sulfaquinoxaline	+	301.3	92.2/156.3	30	30
	sulfameter (IS)	+	281.3	92.2	25	30
	trimethoprim	+	291.5	230.3/261.3	25	23
	tetracycline	+	445.5	410.3/427.3	25	20
	doxycycline	+	445.5	428.2/410.3	25	18
Tetracyclines	oxytetracycline	+	461.5	426.3/443.3	25	20
	<i>chlorotetracycline</i>	+	479.3	444.2/462.1	25	20
	demethyltetracycline (IS)	+ +	465.2	448.3	25	17
	erythromycin spyriamicin	+	734.5 843.5	158.2/576.5 174.0/540.3	25 35	30 35
M	tilmicosin	+	869.3	174.0/340.3	35	45
Macrolides	tylosin	+	917.1	174.2/130.1	35	4 <i>3</i> 35
	•					
	roxithromycin (IS) nalidixic acid	+	837.7	679.5	<u> </u>	30
			233.2	215.1/187.1		14
	flumequine	+	262.2	202.1/244.2	30 20	32
	oxolinic acid	+	262.2	216.1/244.2	30	25
	cinoxacin	+	263.2	217.1/245.2	30	23
	norfloxacin	+	320.3	276.2233.2	20	17
Quinolones	enoxacin	+	321.2	303.2/234.2	35	18
Quinoiones	ciprofloxacin	+	332.2	288.2/245.2	35	17
	danofloxacin	+	358.3	96.1/314.3	33	21
	enrofloxacin	+	360.3	316.3/245.2	31	19
	ofloxacin	+	362.1	261.3/318.2	34	26
	marbofloxacin	+	363.3	72.1/320.2	30	20
	lomefloxacin (IS)	+	352.2	265.3	31	22
	amoxicillin	+	366.3	160.3/114.4	25	20
	oxacillin	+	402.0	243.0/160.0	30	20
Penicillins	nafcillin	+	415.0	199.0/171.0	30	25
<i>````````````````````````````````</i>	dicloxacillin	+	470.0	311.0/160.0	30	25
	penicillin V (IS)	+	351.0	160.2	25	25
	chloramphenicol	_	320.9	151.9/193.9	30	25
Amphenicol	emoramphemeor		520.7	101.7/170.7	20	20

424

425 Table 2 – Maximum Residue Levels (MRLs) set by European Union for liver tissue,

426 validation level (VL) and validation parameters: decision limit (cca), detection

427	capability ( $cc\beta$ ),	repeatability,	reproducibility an	nd recovery.
-----	---------------------------	----------------	--------------------	--------------

	MRL (µg kg <sup>-1</sup> )	VL (μg kg <sup>-1</sup> )	CCα (μg kg <sup>-1</sup> )	СС <b>β</b> (µg kg <sup>-1</sup> )	Repeatability (%RSD)	Reproducibility (%RSD)	Recover (%)
sulfapyridine	100	100	124	149	15	22	101
sulfadiazine	100	100	125	150	15	22	105
sulfamethoxazole	100	100	121	142	15	23	85
sulfathiazole	100	100	115	129	8	12	109
sulfisoxazole	100	100	123	146	16	24	88
sulfamethiazole	100	100	111	122	6	9	108
sulfisomidine	100	100	123	146	13	19	108
sulfamethazine	100	100	115	129	8	12	110
sulfamethoxypyridazine	100	100	114	129	8	12	110
sulfachloropyridazine	100	100	118	135	10	15	107
sulfadoxine	100	100	111	123	7	11	97
sulfadimethoxine	100	100	123	147	13	19	110
sulfanilamide	100	100	125	150	15	22	105
sulfaquinoxaline	100	100	118	137	11	17	98
trimethoprim	50	50	65	81	11	16	88
tetracycline	300	300	322	343	12	18	109
doxycycline	300	300	325	351	14	22	108
oxytetracycline	300	300	313	326	7	11	110
chlorotetracycline	300	300	321	343	15	22	88
erythromycin	200	200	219	237	10	16	109
spyriamicin	300	300	317	333	10	15	102
tilmicosin	1000	1000	1024	1048	13	20	110
tylosin	100	100	111	122	7	10	101
nalidixic acid	-	100	5.81	16.0	15	23	110
flumequine	500	500	528	555	15	23	110
oxolinic acid	150	150	166	182	9	13	109
cinoxacin	-	100	3.10	7.60	15	22	100
norfloxacin	-	100	0.32	0.94	13	19	108
enoxacin	-	100	1.72	3.87	15	22	88
ciprofloxacin	300	300	316	331	11	17	87
danofloxacin	400	400	418	437	12	18	94
enrofloxacin	300	300	325	349	15	22	103
ofloxacin	-	100	0.22	0.65	8	13	81
marbofloxacin	150	150	174	198	14	21	107
amoxicillin	50	50	74	97	15	22	98
oxacillin	300	300	320	339	14	22	83
nafcillin	300	300	321	341	12	17	109
dicloxacillin	300	300	325	349	14	21	109
chloramphenicol	_	0.3	0.28	0.48	11	17	109

428

429

- 430 Figure 1: Individual MRM of one antibiotic per family is given as example from a
- 431 spiked liver sample at the corresponding validation level (100  $\mu$ gkg<sup>-1</sup> for sulfanilamide
- 432 and tylosin; 50  $\mu$ gkg<sup>-1</sup> for trimethoprim and amoxicillin; 300  $\mu$ gkg<sup>-1</sup> for oxitetracycline;
- 433  $0.3 \,\mu g k g^{-1}$  for chloramphenicol and 500  $\mu g k g^{-1}$  for flumequine).

